Acumen Pharmaceuticals Key Executives
This section highlights Acumen Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Acumen Pharmaceuticals
(Showing 0 of )
Acumen Pharmaceuticals Earnings
This section highlights Acumen Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-27 | $-0.47 | $-0.62 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-0.36 | $-0.50 |
| Read Transcript | Q2 | 2024 | 2024-08-13 | $-0.28 | $-0.34 |
| Read Transcript | Q1 | 2024 | 2024-05-14 | $-0.23 | $-0.25 |
| Read Transcript | Q4 | 2023 | 2024-03-26 | $-0.29 | $-0.29 |
| Read Transcript | Q3 | 2023 | 2023-11-13 | $-0.31 | $-0.24 |
| Read Transcript | Q2 | 2023 | 2023-08-11 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-14 | N/A | N/A |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
$1.08
Stock Price
$65.42M
Market Cap
61
Employees
Charlottesville, VA
Location
Financial Statements
Access annual & quarterly financial statements for Acumen Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.44M |
| Cost of Revenue | $- | $184.00K | $169.00K | $4.00K | $8.00K |
| Gross Profit | $- | $-42.32M | $-169.00K | $-4.00K | $1.43M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 99.44% |
| Research and Development Expenses | $93.80M | $42.32M | $32.36M | $12.30M | $8.00M |
| General and Administrative Expenses | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M |
| Other Expenses | $- | $-42.32M | $-11.00K | $51.00K | $- |
| Operating Expenses | $114.02M | $61.14M | $45.24M | $19.58M | $9.35M |
| Cost and Expenses | $114.02M | $61.14M | $45.24M | $19.58M | $9.35M |
| Interest Income | $14.32M | $10.21M | $2.39M | $84.00K | $1.00K |
| Interest Expense | $4.07M | $- | $- | $- | $- |
| Depreciation and Amortization | $178.00K | $184.00K | $169.00K | $4.00K | $7.91M |
| EBITDA | $-98.08M | $-51.61M | $-42.69M | $61.58M | $587.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% |
| Operating Income | $-114.02M | $-61.14M | $-45.24M | $61.57M | $-7.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -550.97% |
| Total Other Income Expenses Net | $11.69M | $8.77M | $2.38M | $-81.02M | $587.00K |
| Income Before Tax | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -510.10% |
| Income Tax Expense | $- | $- | $-2.38M | $81.07M | $-1.00K |
| Net Income | $-102.33M | $-52.37M | $-40.48M | $-181.68M | $-7.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -510.03% |
| EPS | $-1.71 | $-1.08 | $-1.00 | $-4.49 | $-0.18 |
| EPS Diluted | $-1.71 | $-1.08 | $-1.00 | $-4.49 | $-0.18 |
| Weighted Average Shares Outstanding | 60.01M | 48.49M | 40.60M | 40.47M | 40.15M |
| Weighted Average Shares Outstanding Diluted | 60.01M | 48.61M | 40.60M | 40.47M | 40.15M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $290.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.44M | $730.00K | $151.00K | $226.00K |
| Cost of Revenue | $- | $- | $45.00K | $44.00K | $39.00K | $40.00K | $53.00K | $52.00K | $49.00K | $44.00K | $39.00K | $37.00K | $3.00K | $1.00K | $2.25M | $2.53M | $1.03M | $2.99M | $1.93M | $2.05M |
| Gross Profit | $- | $- | $-45.00K | $-44.00K | $251.00K | $-40.00K | $-53.00K | $-52.00K | $-49.00K | $-44.00K | $-39.00K | $-37.00K | $-3.00K | $-1.00K | $-2.25M | $-2.53M | $410.00K | $-2.26M | $-1.78M | $-1.82M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 86.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 28.55% | -310.14% | -1176.16% | -807.08% |
| Research and Development Expenses | $34.57M | $27.25M | $19.53M | $12.45M | $13.29M | $11.18M | $9.13M | $8.71M | $10.75M | $8.31M | $7.32M | $5.99M | $5.67M | $1.80M | $2.25M | $2.58M | $1.03M | $2.99M | $1.93M | $2.05M |
| General and Administrative Expenses | $5.03M | $5.02M | $4.85M | $5.33M | $5.19M | $4.86M | $4.34M | $4.42M | $3.50M | $3.06M | $3.09M | $3.22M | $2.74M | $2.13M | $1.19M | $1.22M | $644.00K | $226.00K | $259.00K | $222.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $-39.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.03M | $5.02M | $4.85M | $5.33M | $5.15M | $4.86M | $4.34M | $4.42M | $3.50M | $3.06M | $3.09M | $3.22M | $2.74M | $2.13M | $1.19M | $1.22M | $644.00K | $226.00K | $259.00K | $222.00K |
| Other Expenses | $- | $- | $- | $-54.00K | $-21.00K | $-42.00K | $-16.00K | $-4.00K | $-10.00K | $-2.00K | $- | $1.00K | $4.00K | $19.00K | $19.00K | $9.00K | $1.11M | $- | $- | $- |
| Operating Expenses | $39.60M | $32.27M | $24.38M | $17.77M | $18.45M | $16.04M | $13.48M | $13.13M | $14.25M | $11.37M | $10.41M | $9.21M | $8.41M | $3.94M | $3.44M | $3.79M | $2.78M | $2.49M | $2.19M | $2.27M |
| Cost and Expenses | $39.60M | $32.27M | $24.38M | $17.77M | $18.49M | $16.04M | $13.48M | $13.13M | $14.25M | $11.37M | $10.41M | $9.21M | $8.41M | $3.94M | $3.44M | $3.79M | $2.78M | $2.49M | $2.19M | $2.27M |
| Interest Income | $2.99M | $3.50M | $3.82M | $4.00M | $3.95M | $3.12M | $1.88M | $1.83M | $1.39M | $663.00K | $260.00K | $76.00K | $39.00K | $37.00K | $4.00K | $4.00K | $- | $- | $- | $1.00K |
| Interest Expense | $1.04M | $1.03M | $1.00M | $1.00M | $581.00K | $- | $- | $- | $- | $663.00K | $- | $76.00K | $- | $23.00K | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $44.00K | $45.00K | $45.00K | $44.00K | $39.00K | $40.00K | $53.00K | $52.00K | $49.00K | $44.00K | $39.00K | $37.00K | $3.00K | $1.00K | $3.44M | $3.79M | $1.34M | $2.49M | $2.04M | $2.05M |
| EBITDA | $-36.07M | $-28.69M | $-19.49M | $-13.83M | $-13.47M | $-16.04M | $-11.56M | $-11.26M | $-14.24M | $-11.37M | $-10.41M | $-9.17M | $-8.37M | $-3.94M | $-3.44M | $-3.79M | $-1.34M | $-2.49M | $-2.04M | $1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4645.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -93.45% | -341.10% | -1347.68% | -905.31% |
| Operating Income | $-39.60M | $-32.27M | $-24.38M | $-17.77M | $-18.49M | $-16.04M | $-13.48M | $-13.13M | $-14.25M | $-11.37M | $-10.41M | $-9.21M | $-8.41M | $-3.94M | $-3.44M | $-3.79M | $-1.34M | $-2.49M | $-2.04M | $-2.05M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -6374.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -93.38% | -341.10% | -1347.68% | -905.31% |
| Total Other Income Expenses Net | $2.44M | $2.50M | $3.84M | $2.90M | $1.99M | $3.08M | $1.87M | $1.83M | $1.38M | $661.00K | $260.00K | $77.00K | $66.00K | $33.00K | $-57.92M | $-23.20M | $586.00K | $- | $- | $1.00K |
| Income Before Tax | $-37.15M | $-29.77M | $-20.54M | $-14.87M | $-16.50M | $-12.96M | $-11.61M | $-11.31M | $-12.87M | $-10.71M | $-10.15M | $-9.13M | $-8.35M | $-3.90M | $-61.36M | $-27.00M | $-755.00K | $-2.49M | $-2.04M | $-2.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -5688.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -52.58% | -341.10% | -1347.68% | -904.87% |
| Income Tax Expense | $- | $- | $- | $-44.00K | $3.75M | $-40.00K | $-1.88M | $-1.83M | $998.00K | $-661.00K | $-260.00K | $-77.00K | $-66.00K | $-56.00K | $57.92M | $23.20M | $-586.00K | $-2.49M | $-2.04M | $-1.00K |
| Net Income | $-37.15M | $-29.77M | $-20.54M | $-14.87M | $-16.50M | $-12.96M | $-11.61M | $-9.48M | $-13.86M | $-10.05M | $-9.89M | $-9.05M | $-8.35M | $-3.90M | $-61.36M | $-27.00M | $-755.00K | $-2.49M | $-2.04M | $-2.04M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -5688.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -52.58% | -341.10% | -1347.68% | -904.87% |
| EPS | $0.00 | $-0.50 | $-0.34 | $-0.25 | $-0.28 | $-0.24 | $-0.28 | $-0.23 | $-0.34 | $-0.25 | $-0.24 | $-0.22 | $-0.22 | $-0.10 | $-1.59 | $-0.73 | $-0.03 | $-0.09 | $-0.07 | $-0.07 |
| EPS Diluted | $0.00 | $-0.50 | $-0.34 | $-0.25 | $-0.28 | $-0.24 | $-0.28 | $-0.23 | $-0.34 | $-0.25 | $-0.24 | $-0.22 | $-0.22 | $-0.10 | $-1.59 | $-0.73 | $-0.03 | $-0.09 | $-0.07 | $-0.07 |
| Weighted Average Shares Outstanding | - | 60.08M | 60.08M | 59.81M | 57.91M | 54.23M | 41.03M | 41.03M | 40.86M | 40.50M | 40.50M | 40.47M | 38.27M | 38.27M | 38.65M | 36.99M | 28.65M | 28.65M | 28.65M | 28.65M |
| Weighted Average Shares Outstanding Diluted | - | 60.08M | 60.08M | 59.81M | 57.91M | 54.23M | 41.03M | 41.03M | 40.86M | 40.50M | 40.50M | 40.47M | 38.27M | 38.27M | 38.65M | 36.99M | 28.65M | 28.65M | 28.65M | 28.65M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $35.63M | $66.89M | $130.10M | $122.16M | $43.78M |
| Short Term Investments | $135.93M | $176.64M | $47.50M | $72.08M | $- |
| Cash and Short Term Investments | $171.56M | $243.52M | $177.60M | $194.24M | $43.78M |
| Net Receivables | $- | $225.00K | $- | $- | $109.00K |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $6.75M | $2.87M | $2.72M | $4.42M | $543.00K |
| Total Current Assets | $178.31M | $246.62M | $180.33M | $198.66M | $44.43M |
| Property Plant Equipment Net | $339.00K | $503.00K | $270.00K | $36.00K | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $62.55M | $15.84M | $31.62M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $60.35M | $454.00K | $151.00K | $14.00K | $- |
| Total Non-Current Assets | $60.69M | $63.51M | $16.26M | $31.67M | $- |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M |
| Account Payables | $5.65M | $1.38M | $1.64M | $1.09M | $531.00K |
| Short Term Debt | $133.00K | $1.73M | $210.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $21.83M | $9.86M | $5.96M | $4.06M | $5.84M |
| Total Current Liabilities | $27.61M | $12.97M | $7.81M | $5.15M | $6.37M |
| Long Term Debt | $28.60M | $27.62M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $970.00K | $2.56M | $- | $- | $56.65M |
| Total Non-Current Liabilities | $29.57M | $30.18M | $- | $- | $56.65M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $57.18M | $43.15M | $7.81M | $5.15M | $63.02M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $4.00K | $4.00K | $- |
| Retained Earnings | $-325.13M | $-222.80M | $-170.43M | $-127.57M | $-26.96M |
| Accumulated Other Comprehensive Income Loss | $-48.00K | $312.00K | $-751.00K | $-231.00K | $- |
| Other Total Stockholders Equity | $506.99M | $489.45M | $359.95M | $352.98M | $65.03M |
| Total Stockholders Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M |
| Total Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M |
| Total Liabilities and Stockholders Equity | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M |
| Total Investments | $135.93M | $239.19M | $63.34M | $103.69M | $- |
| Total Debt | $28.73M | $28.49M | $105.00K | $- | $- |
| Net Debt | $-6.89M | $-38.40M | $-130.00M | $-122.16M | $-43.78M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $35.63M | $33.18M | $67.95M | $46.93M | $66.89M | $94.92M | $77.25M | $78.00M | $130.10M | $157.54M | $111.07M | $108.76M | $122.16M | $135.80M | $68.81M | $41.41M | $43.78M | $-6.55M |
| Short Term Investments | $135.93M | $167.16M | $192.52M | $205.58M | $176.64M | $120.52M | $67.63M | $62.41M | $47.50M | $42.65M | $78.84M | $80.33M | $72.08M | $64.16M | $- | $- | $- | $13.10M |
| Cash and Short Term Investments | $171.56M | $200.34M | $260.47M | $252.51M | $243.52M | $215.43M | $144.88M | $140.41M | $177.60M | $200.19M | $189.91M | $189.09M | $194.24M | $199.96M | $68.81M | $41.41M | $43.78M | $6.55M |
| Net Receivables | $398.00K | $- | $106.00K | $189.00K | $225.00K | $- | $- | $- | $- | $- | $- | $- | $- | $109.00K | $109.00K | $109.00K | $109.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $6.35M | $7.29M | $6.34M | $3.13M | $2.87M | $3.16M | $4.66M | $3.62M | $2.72M | $2.37M | $1.14M | $3.01M | $4.42M | $4.84M | $1.65M | $1.00M | $543.00K | $- |
| Total Current Assets | $178.31M | $207.63M | $266.92M | $255.83M | $246.62M | $218.60M | $149.54M | $144.03M | $180.33M | $202.56M | $191.05M | $192.10M | $198.66M | $204.91M | $70.57M | $42.10M | $44.43M | $6.55M |
| Property Plant Equipment Net | $339.00K | $385.00K | $430.00K | $470.00K | $503.00K | $125.00K | $165.00K | $218.00K | $270.00K | $275.00K | $280.00K | $252.00K | $36.00K | $13.00K | $6.00K | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $184.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $184.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $59.97M | $58.55M | $20.91M | $44.11M | $62.55M | $67.27M | $27.31M | $43.42M | $15.84M | $- | $20.00M | $27.66M | $31.62M | $29.91M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-184.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $379.00K | $406.00K | $476.00K | $558.00K | $454.00K | $378.00K | $391.00K | $195.00K | $151.00K | $429.00K | $344.00K | $79.00K | $14.00K | $13.00K | $2.37M | $270.00K | $- | $-6.55M |
| Total Non-Current Assets | $60.69M | $59.34M | $22.00M | $45.14M | $63.51M | $67.77M | $27.87M | $43.83M | $16.26M | $704.00K | $20.62M | $27.99M | $31.67M | $29.94M | $2.37M | $270.00K | $- | $-6.55M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $238.99M | $266.98M | $288.91M | $300.97M | $310.12M | $286.37M | $177.41M | $187.86M | $196.59M | $203.26M | $211.68M | $220.09M | $230.33M | $234.85M | $72.94M | $42.37M | $44.43M | $- |
| Account Payables | $5.65M | $2.34M | $4.21M | $3.08M | $1.38M | $1.36M | $2.03M | $762.00K | $1.64M | $2.08M | $1.71M | $1.22M | $1.09M | $382.00K | $2.91M | $918.00K | $531.00K | $- |
| Short Term Debt | $133.00K | $129.00K | $250.00K | $242.00K | $1.73M | $4.00K | $58.00K | $134.00K | $210.00K | $266.00K | $284.00K | $278.00K | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-125.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $21.83M | $17.44M | $10.91M | $5.15M | $9.86M | $4.73M | $6.45M | $7.88M | $5.96M | $4.26M | $3.14M | $2.44M | $4.06M | $1.11M | $1.61M | $30.26M | $5.84M | $- |
| Total Current Liabilities | $27.61M | $19.91M | $15.37M | $8.47M | $12.97M | $6.10M | $8.53M | $8.78M | $7.81M | $6.61M | $5.13M | $3.94M | $5.15M | $1.49M | $4.52M | $31.18M | $6.37M | $- |
| Long Term Debt | $28.60M | $29.86M | $28.09M | $27.85M | $27.62M | $- | $- | $- | $- | $- | $50.00K | $124.00K | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $970.00K | $- | $1.51M | $2.61M | $2.56M | $- | $- | $- | $- | $- | $-25.00K | $-62.00K | $- | $- | $174.50M | $56.65M | $56.65M | $- |
| Total Non-Current Liabilities | $29.57M | $29.86M | $29.60M | $30.46M | $30.18M | $- | $- | $- | $- | $- | $25.00K | $62.00K | $- | $- | $174.50M | $56.65M | $56.65M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $57.18M | $49.77M | $44.97M | $38.93M | $43.15M | $6.10M | $8.53M | $8.78M | $7.81M | $6.61M | $5.16M | $4.00M | $5.15M | $1.49M | $179.02M | $87.83M | $63.02M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $17.40M |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $- | $- | $- | $- |
| Retained Earnings | $-325.13M | $-287.97M | $-258.21M | $-237.67M | $-222.80M | $-206.30M | $-193.34M | $-181.73M | $-170.43M | $-157.56M | $-146.85M | $-136.70M | $-127.57M | $-119.22M | $-115.32M | $-53.96M | $-26.96M | $- |
| Accumulated Other Comprehensive Income Loss | $-48.00K | $518.00K | $-164.00K | $-144.00K | $312.00K | $-509.00K | $-646.00K | $-524.00K | $-751.00K | $-965.00K | $-965.00K | $-814.00K | $-231.00K | $-28.00K | $- | $- | $- | $-11.42M |
| Other Total Stockholders Equity | $506.99M | $504.65M | $502.31M | $499.84M | $489.45M | $487.08M | $362.86M | $361.34M | $359.95M | $355.17M | $354.33M | $353.60M | $352.98M | $352.61M | $9.24M | $65.15M | $8.37M | $- |
| Total Stockholders Equity | $181.82M | $217.20M | $243.95M | $262.03M | $266.97M | $280.27M | $168.87M | $179.09M | $188.78M | $196.65M | $206.52M | $216.09M | $225.18M | $233.36M | $-106.08M | $-45.46M | $-18.59M | $5.98M |
| Total Equity | $181.82M | $217.20M | $243.95M | $262.03M | $266.97M | $280.27M | $168.87M | $179.09M | $188.78M | $196.65M | $206.52M | $216.09M | $- | $- | $- | $- | $- | $5.98M |
| Total Liabilities and Stockholders Equity | $238.99M | $266.98M | $288.91M | $300.97M | $310.12M | $286.37M | $177.41M | $187.86M | $196.59M | $203.26M | $211.68M | $220.09M | $230.33M | $234.85M | $72.94M | $42.37M | $44.43M | $5.98M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $238.99M | $266.98M | $288.91M | $300.97M | $310.12M | $286.37M | $177.41M | $187.86M | $196.59M | $203.26M | $211.68M | $220.09M | $230.33M | $234.85M | $72.94M | $42.37M | $44.43M | $5.98M |
| Total Investments | $195.90M | $225.71M | $213.43M | $249.69M | $239.19M | $187.79M | $94.94M | $105.83M | $63.34M | $42.65M | $98.84M | $107.98M | $103.69M | $94.07M | $- | $- | $- | $13.10M |
| Total Debt | $28.73M | $29.99M | $28.21M | $27.97M | $28.49M | $2.00K | $29.00K | $67.00K | $105.00K | $133.00K | $167.00K | $201.00K | $- | $- | $- | $- | $- | $- |
| Net Debt | $-6.89M | $-3.20M | $-39.74M | $-18.96M | $-38.40M | $-94.92M | $-77.22M | $-77.93M | $-130.00M | $-157.41M | $-110.90M | $-108.56M | $-122.16M | $-135.80M | $-68.81M | $-41.41M | $-43.78M | $6.55M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M |
| Depreciation and Amortization | $178.00K | $184.00K | $169.00K | $4.00K | $- |
| Deferred Income Tax | $- | $- | $- | $155.00K | $- |
| Stock Based Compensation | $9.63M | $6.14M | $3.06M | $922.00K | $154.00K |
| Change in Working Capital | $11.65M | $3.87M | $3.99M | $298.00K | $307.00K |
| Accounts Receivables | $- | $- | $- | $- | $-79.00K |
| Inventory | $- | $- | $- | $- | $79.00K |
| Accounts Payables | $4.27M | $-261.00K | $552.00K | $557.00K | $308.00K |
| Other Working Capital | $7.38M | $4.13M | $3.43M | $-259.00K | $-1.00K |
| Other Non Cash Items | $-5.35M | $-888.00K | $487.00K | $81.27M | $-586.00K |
| Net Cash Provided by Operating Activities | $-86.22M | $-43.06M | $-35.15M | $-17.96M | $-7.45M |
| Investments in Property Plant and Equipment | $-16.00K | $-21.00K | $-161.00K | $-40.00K | $- |
| Acquisitions Net | $- | $- | $-39.35K | $- | $- |
| Purchases of Investments | $-170.73M | $-250.63M | $-41.51M | $-104.08M | $- |
| Sales Maturities of Investments | $218.77M | $78.98M | $80.86M | $- | $- |
| Other Investing Activities | $- | $3.00K | $39.35K | $-104.08K | $- |
| Net Cash Used for Investing Activities | $48.03M | $-171.67M | $39.19M | $-104.12M | $- |
| Debt Repayment | $-739.00K | $30.00M | $- | $- | $- |
| Common Stock Issued | $7.94M | $121.90M | $3.79M | $168.56M | $44.67M |
| Common Stock Repurchased | $-41.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-230.00K | $-151.00K | $115.00K | $31.91M | $44.67M |
| Net Cash Used Provided by Financing Activities | $6.93M | $151.75M | $3.91M | $200.47M | $44.67M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-31.26M | $-62.98M | $7.94M | $78.39M | $37.23M |
| Cash at End of Period | $35.86M | $67.12M | $130.10M | $122.16M | $43.78M |
| Cash at Beginning of Period | $67.12M | $130.10M | $122.16M | $43.78M | $6.55M |
| Operating Cash Flow | $-86.22M | $-43.06M | $-35.15M | $-17.96M | $-7.45M |
| Capital Expenditure | $-16.00K | $-21.00K | $-161.00K | $-40.00K | $- |
| Free Cash Flow | $-86.23M | $-43.09M | $-35.31M | $-18.00M | $-7.45M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-37.15M | $-29.77M | $-20.54M | $-14.87M | $-16.50M | $-12.96M | $-11.61M | $-11.31M | $-12.87M | $-10.71M | $-10.15M | $-9.13M | $-8.35M | $-3.90M | $-61.36M | $-27.00M | $-755.00K | $-2.49M | $-2.04M | $-2.04M |
| Depreciation and Amortization | $44.00K | $45.00K | $45.00K | $44.00K | $39.00K | $40.00K | $53.00K | $52.00K | $49.00K | $44.00K | $39.00K | $37.00K | $3.00K | $1.00K | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-1.70M | $890.00K | $415.00K | $- | $- | $- | $- | $- | $134.00K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $2.34M | $2.34M | $2.47M | $2.48M | $1.63M | $1.60M | $1.52M | $1.39M | $888.00K | $840.00K | $715.00K | $618.00K | $365.00K | $304.00K | $127.00K | $126.00K | $38.00K | $39.00K | $38.00K | $39.00K |
| Change in Working Capital | $8.22M | $3.73M | $3.77M | $-4.07M | $6.05M | $-878.00K | $-1.33M | $24.00K | $814.00K | $452.00K | $2.76M | $-41.00K | $4.07M | $-4.08M | $-973.00K | $1.28M | $-1.55M | $1.17M | $503.00K | $190.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $108.00K | $-217.00K | $256.00K | $-226.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $3.31M | $-1.86M | $1.12M | $1.70M | $17.00K | $-662.00K | $1.26M | $-878.00K | $-444.00K | $416.00K | $459.00K | $121.00K | $706.00K | $-890.00K | $354.00K | $387.00K | $-923.00K | $851.00K | $227.00K | $153.00K |
| Other Working Capital | $4.92M | $5.59M | $2.64M | $-5.77M | $6.04M | $-216.00K | $-2.60M | $902.00K | $1.26M | $36.00K | $2.30M | $-162.00K | $3.37M | $-3.19M | $-1.33M | $897.00K | $-631.00K | $317.00K | $276.00K | $37.00K |
| Other Non Cash Items | $-669.00K | $-948.00K | $-2.29M | $-575.00K | $2.15M | $-1.60M | $-715.00K | $-334.00K | $-88.00K | $191.00K | $168.00K | $216.00K | $136.00K | $-5.00K | $57.94M | $23.22M | $-586.00K | $851.00K | $226.00K | $153.00K |
| Net Cash Provided by Operating Activities | $-27.21M | $-24.60M | $-16.55M | $-17.86M | $-8.31M | $-12.90M | $-11.67M | $-10.18M | $-11.20M | $-9.18M | $-6.47M | $-8.30M | $-3.64M | $-7.69M | $-4.26M | $-2.37M | $-2.86M | $-1.28M | $-1.49M | $-1.82M |
| Investments in Property Plant and Equipment | $- | $- | $-5.00K | $-11.00K | $-14.00K | $-7.00K | $- | $- | $-35.00K | $-81.00K | $-36.00K | $-9.00K | $-26.00K | $-8.00K | $-6.00K | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $-3.00K | $3.00K | $- | $- | $20.39K | $- | $-8.82K | $- | $-94.09M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-15.10M | $-98.54M | $-11.80M | $-45.29M | $-71.78M | $-126.73M | $- | $-52.13M | $-29.39M | $- | $-3.04M | $-9.09M | $-9.98M | $-94.09M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $44.76M | $88.41M | $49.51M | $36.10M | $22.98M | $34.73M | $11.06M | $10.20M | $9.00M | $56.00M | $11.86M | $4.00M | $-104.08M | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-9.19M | $-48.79K | $-91.99K | $11.06K | $-41.93K | $-20.39K | $56.00K | $8.82K | $-5.09M | $198.18M | $-94.09M | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $29.66M | $-10.13M | $37.70M | $-9.20M | $-48.81M | $-92.00M | $11.06M | $-41.93M | $-20.42M | $55.92M | $8.79M | $-5.10M | $-10.01M | $-94.10M | $-6.00K | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $-739.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $188.00K | $-128.00K | $7.94M | $-390.00K | $122.29M | $-145.00K | $- | $3.79M | $-263.00K | $-14.00K | $- | $-3.00K | $168.78M | $31.68M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-9.00K | $- | $- | $-32.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-42.00K | $-128.00K | $-60.00K | $29.52M | $470.00K | $- | $- | $392.00K | $-263.00K | $-14.00K | $- | $13.00K | $168.78M | $31.68M | $- | $44.67M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-9.00K | $-42.00K | $-128.00K | $7.11M | $29.13M | $122.76M | $-145.00K | $- | $4.18M | $-263.00K | $-14.00K | $- | $10.00K | $168.78M | $31.68M | $- | $44.67M | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-44.00K | $-16.26M | $- | $- | $- | $- | $- | $- | $6.00K | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $2.44M | $-34.53M | $21.02M | $-19.96M | $-28.03M | $17.86M | $-751.00K | $-52.10M | $-27.44M | $46.47M | $2.30M | $-13.40M | $-13.64M | $66.99M | $27.41M | $-2.37M | $41.82M | $-1.28M | $-1.49M | $-1.82M |
| Cash at End of Period | $35.86M | $33.42M | $67.95M | $46.93M | $66.89M | $95.11M | $77.25M | $78.00M | $130.10M | $157.54M | $111.07M | $108.76M | $122.16M | $135.80M | $68.81M | $41.41M | $43.78M | $1.96M | $3.24M | $4.74M |
| Cash at Beginning of Period | $33.42M | $67.95M | $46.93M | $66.89M | $94.92M | $77.25M | $78.00M | $130.10M | $157.54M | $111.07M | $108.76M | $122.16M | $135.80M | $68.81M | $41.41M | $43.78M | $1.96M | $3.24M | $4.74M | $6.55M |
| Operating Cash Flow | $-27.21M | $-24.60M | $-16.55M | $-17.86M | $-8.31M | $-12.90M | $-11.67M | $-10.18M | $-11.20M | $-9.18M | $-6.47M | $-8.30M | $-3.64M | $-7.69M | $-4.26M | $-2.37M | $-2.86M | $-1.28M | $-1.49M | $-1.82M |
| Capital Expenditure | $- | $- | $-5.00K | $-11.00K | $-14.00K | $-7.00K | $- | $- | $-35.00K | $-81.00K | $-36.00K | $-9.00K | $-26.00K | $-8.00K | $-6.00K | $- | $- | $- | $- | $- |
| Free Cash Flow | $-27.21M | $-24.60M | $-16.55M | $-17.87M | $-8.33M | $-12.91M | $-11.67M | $-10.18M | $-11.24M | $-9.26M | $-6.50M | $-8.31M | $-3.67M | $-7.70M | $-4.27M | $-2.37M | $-2.86M | $-1.28M | $-1.49M | $-1.82M |
Acumen Pharmaceuticals Dividends
Explore Acumen Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Acumen Pharmaceuticals News
Read the latest news about Acumen Pharmaceuticals, including recent articles, headlines, and updates.
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference. The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen's Phase 1 INTERCEPT-AD trial, which did not use this approach. Furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid PET scans or lumbar puncture (LP) procedures among people who are not eligible to continue in screening.
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD.
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Alex Braun - Head of Investor Relations Conference Call Participants Tom Shrader - BTIG Cameron Bozdog - Bank of America Samantha Schaeffer - Cantor Fitzgerald Trung Huynh - UBS Ananda Ghosh - HC Wainwright Operator Hello, and thank you for standing by.
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug's Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease.
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer's disease (AD), today announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study. The study plans to compare the PK between subcutaneous and intravenous administrations of sabirnetug in healthy volunteers.
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug's mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (CSF). The posters will be presented at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28-Aug. 1, 2024.
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Alex Braun - Vice President & Head of Investor Relations Daniel O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Eric Siemers - Chief Medical Officer Conference Call Participants Tom Shrader - BTIG Samantha Schaeffer - Cantor Fitzgerald Jason Zemansky - Bank of America Operator Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast.
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen's prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
CHARLOTTESVILLE, Va. and BASEL, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ABOS.